When was Innovheart founded?

Innovheart was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Innovheart located?

Innovheart is headquartered in Milano, Italy.

Who is the current CEO of Innovheart?

David J. Wilson of Innovheart. They have also founded 1 company.

How many employees does Innovheart have?

As of Sep 30, 2026, the latest employee count at Innovheart is 30.

Is Innovheart a funded company?

Innovheart is a funded company, having raised a total of $78.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2015.

When was the latest funding round of Innovheart?

Innovheart's latest funding was a $***** Series C round on Jan 27, 2022, with participation from 4 investors.

What is the annual revenue of Innovheart?

Annual revenue of Innovheart is between €1M and €10M as on Dec 31, 2023

Where does Innovheart rank among its competitors?

Innovheart ranks 11th amongst 113 active competitors, of which 50 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Pi-Cardia, which secured an undisclosed amount in Sep, 2026.

Innovheart - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Who are the top competitors of Innovheart?

Innovheart's top competitors include Shockwave Medical, MicroPort CardioFlow Medtech Corporation and Peijia Medical Technologies. Among them, Pi-Cardia secured the most recent funding round in September, 2026.

Innovheart is a series C company based in Milano (Italy), founded in 2015 by Giovanni Righini and David J. Wilson. It operates as a Provider of aesthetic devices for the treatment of atrioventricular valve diseases. Innovheart has raised $78.7M in funding from investors like Genextra, China Grand Pharmaceutical and Healthcare and Panakes Partners. The company has 113 active competitors, including 50 funded and 29 that have exited. Its top competitors include companies like Shockwave Medical, MicroPort CardioFlow Medtech Corporation and Peijia Medical Technologies.

Company Details

Provider of aesthetic devices for the treatment of atrioventricular valve diseases. The company has developed a novel solution for mitral valve replacement. The device helps to manage structural stabilization, low LVOT, obstruction risk, and low risk of SAM.

Website: www.innovheart.com/
Social
Email ID: *****@innovheart.com
Phone Number: +39 **********

Key Metrics

Founded Year

2015

Location

Milano, Italy

Stage

Series C

Total Funding

$78.7M in 3 rounds

Latest Funding Round

Series C, Jan 27, 2022, $*****

Investors

Genextra & 6 more

Ranked

11^th among 113 active competitors

Annual Revenue

€1M - €10M as on Dec 31, 2023

Employee Count

30 as on Sep 30, 2026

Similar Companies

Shockwave Medical & 147 more

View Innovheart's full profile

Innovheart is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Innovheart Srl CIN: 9291430966 , Italy, Active	Jan 01, 2015	€1M - €10M (As on Dec 31, 2023)	-	-
ROBOTHEFI MEDIA SRL CIN: 5031610 , Romania, Active		-	8 (As on Dec 31, 2023)	-

Innovheart has raised a total funding of $78.7M over 3 rounds. Its first funding round was on 2015. Its latest funding round was a Series C round on Jan 27, 2022 for $*****. 4 investors participated in its latest round. Innovheart has 7 institutional investors.

Here is the list of recent funding rounds of Innovheart:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2022	7373653	Series C	3657788	7476760	9341374	3652579
Aug 07, 2020	8675740	Series B	8620065	1531757	3527529	Cassa depositi e prestiti Group & 2 more
2015	8059	Series A	8326	8569	Genextra	3599

Access funding benchmarks and valuations. Sign up today!

View details of Innovheart's funding rounds and investors

The founders of Innovheart are Giovanni Righini and David J. Wilson. David J. Wilson is the CEO of Innovheart.

Here are the details of Innovheart's key team members:

Giovanni Righini: Founder & CTO of Innovheart.
David J. Wilson: CEO of Innovheart.

View details of Innovheart's Founder profiles and Board Members

Innovheart's employee count trend

Innovheart has 30 employees as of Sep 26. Here is Innovheart's employee count trend over the years:

Uncover Innovheart's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Innovheart include Shockwave Medical, MicroPort CardioFlow Medtech Corporation and Peijia Medical Technologies. Here is the list of Top 10 competitors of Innovheart, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Shockwave Medical 2009, Santa Clara (United States), Acquired	Developer of cardiovascular balloon dilation catheters	$148M	Sofinnova Partners, Venrock & 9 others	65/100
2nd	MicroPort CardioFlow Medtech Corporation 2015, Pudong (China), Public	Developer of smart medical devices for patients with heart valve diseases	$132M	Lake Bleu Capital, CICC & 10 others	63/100
3rd	Peijia Medical Technologies 2012, Suzhou (China), Public	Developer of medical devices for the treatment of cardiac and cerebrovascular diseases	$110M	Lilly Asia Ventures, SDIC Innovation & 9 others	63/100
4th	Cardiac Dimensions 2001, Kirkland (United States), Series E	Developer of invasive cardiac implants for heart failure	$261M	Life Sciences Partners, Lumira Ventures & 20 others	62/100
5th	JenaValve Technology 2006, Irvine (United States), Acquired	Provider of pericardial transcatheter aortic valve replacement and delivery system	$364M	Sunstone, Valiance Asset Management & 19 others	62/100
6th	Pi-Cardia 2009, Rehovot (Israel), Series D	Developer of non-implant device for valve repair	$40M	Clal Biotechnology Industries, Sofinnova Partners ... & 9 others	62/100
7th	Venus MedTech 2009, Hangzhou (China), Public	Transcatheter aortic valves	$37M	DCP, HongShan & 6 others	62/100
8th	CroiValve 2016, Dublin (Ireland), Series B	Developer of a percutaneous device for treating tricuspid regurgitation	$52.1M	Irrus Investments, Halo Business Angel Network ... & 21 others	58/100
9th	TRiCares 2013, Aschheim (Germany), Series D	Developer of a minimally invasive tricuspid valve replacement system. This system is designed to treat tricuspid regurgitation, a serious heart condition, without the need for open-heart surgery. The company focuses on developing a safe and effective solution to address the limitations of existing treatment approaches. It is developing a catheter-based system for tricuspid valve replacement. The company's efforts include clinical trials and securing funding to support further development and clinical milestones.	$103M	415 CAPITAL, Lifeblood Capital & 10 others	58/100
10th	HighLife Medical 2010, Paris (France), Series B	Developer of trans-catheter mitral valve replacement system	$50.8M	USVP, Sofinnova Partners & 7 others	56/100
11th	Innovheart 2015, Milano (Italy), Series C	Provider of aesthetic devices for the treatment of atrioventricular valve diseases	$78.7M	Indaco Venture Partners, Panakes Partners ... & 5 others	56/100